Cadazolid (ACT-179811)

Description: Cadazolid, also known ACT-179811, is a novel fluoroquinolone-oxazolidinone antibiotic and a protein synthesis inhibitor. Cadazolid may be potentially useful for the treatment of Clostridium difficile infection. Cadazolid exhibits potent in vitro activity against Clostridium difficile, including the epidemic BI/NAP1/027 strain. Clostridium difficile infection (CDI), the main cause of nosocomial infectious diarrhea, results from the growth of toxin-producing C. difficile in the colon following disruption of the normal enteric microbiota, usually as a consequence of antibiotic therapy.

References: Seiler P, Enderlin-Paput M, Pfaff P, Weiss M, Ritz D, Clozel M, Locher HH. Cadazolid does not promote intestinal colonization of vancomycin-resistant enterococci in mice. Antimicrob Agents Chemother. 2015 Oct 26. pii: AAC.01923-15. Epub ahead of print PubMed PMID: 26503650.